Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stereotactic Ablative Body Radiotherapy (SABR) Combined with Immunotherapy (L19-IL2) in Stage IV NSCLC Patients, ImmunoSABR: a Multicentre, Randomised Controlled Open-label Phase II Trial

NCT03705403 is registered in ClinicalTrials.gov with Maastricht University Medical Center as lead sponsor.

NCT NCT03705403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03705403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stereotactic Ablative Body Radiotherapy (SABR) Combined with Immunotherapy (L19-IL2) in Stage IV NSCLC Patients, ImmunoSABR: a Multicentre, Randomised Controlled Open-label Phase II Trial
Lead sponsor
Maastricht University Medical Center
Phase
Phase 2
Overall status
Terminated
Start date
April 4, 2019
Completion date
January 6, 2025
Enrollment
88 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic disease, nsclc stage iv